Safety, Efficacy of Robotic vs Open Liver Resection for Hepatocellular Carcinoma

JAMA Surgery

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, NOVEMBER 23, 2022

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2022.5697?guestAccessKey=2db7ccf1-7c2d-4280-98e0-b9cdc8b2d151&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=112322

 

About The Study: The findings of this study comparing robotic liver resection with open liver resection suggest that robotic liver resection is a safe treatment strategy for patients with hepatocellular carcinoma, the most common type of primary liver cancer, and those with compromised liver function while achieving oncologic efficacy. 

Authors: Fabrizio Di Benedetto, M.D., and Stefano Di Sandro, M.D., of the University of Modena and Reggio Emilia in Modena, Italy, are the corresponding authors.

 

(doi:10.1001/jamasurg.2022.5697)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.